protein

Recombinant Glycocalicin (GC)

MBS2012079

0.01 mg

200 USD

Recombinant Protein

Recombinant Glycocalicin (GC)

Glycocalicin (GC)

Platelet glycoprotein Ib alpha chain; Platelet glycoprotein Ib alpha chain; platelet glycoprotein Ib alpha chain; GP-Ib alpha; antigen CD42b-alpha; platelet membrane glycoprotein 1b-alpha subunit; glycoprotein Ib (platelet), alpha polypeptide; Antigen CD42b-alpha

GC

GP1BA; GP1BA; BSS; GP1B; VWDP; CD42B; GPIbA; BDPLT1; BDPLT3; DBPLT3; CD42b-alpha; GP-Ib alpha; GPIb-alpha; GPIbA

GP1BA_HUMAN

E Coli

626

The target protein is fused with N-terminal His-Tag, its sequence is listed below. MGHHHHHHSGSEF-LRGLG ELQELYLKGN ELKTLPPGLL TPTPKLEKLS LANNNLTELP AGLLNGLENL DTLLLQENSL YTIPKGFFGS HLLPFAFLHG NPWLCNCEIL YFRRWLQDNA ENVYVWKQGV DVKAMTSNVA SVQCDNSDKF PVYKYP

> 95%

Supplied as lyophilized form in PBS, pH8.0, containing 5% sucrose, 0.02% sarcosyl.

Avoid repeated freeze/thaw cycles. Store at 2-8 degree C for one month. Aliquot and store at -80 degree C for 12 months. Stability Test: The thermal stability is described by the loss rate of the targetprotein. The loss rate was determined by accelerated thermal degradation test,that is, incubate the protein at 37 degree C for 48h, and no obvious degradation andprecipitation were observed. (Referring from China Biological Products Standard,which was calculated by the Arrhenius equation.) The loss of this protein is lessthan 5% within the expiration date under appropriate storage condition.

SDS-PAGE, Western Blot (WB), ELISA (EIA), Immunoprecipitation (IP). (May be suitable for use in other assays to be determined by the end user.)

Organism: Homo sapiens (Human). Expression System: Prokaryotic expression. Residues: Leu136~Pro276 (Accession # P07359) with N-terminal His-Tag. Predicted isoelectric point: 6.2

Endotoxin Level: <1.0EU per 1ug (determined by the LAL method). Reconstitution: Reconstitute in sterile PBS, pH7.2-pH7.4. Usage: Reconstitute in sterile PBS

About the Marker: Effective Size Range: 10kDa to 70kDa. Protein bands: 10kDa, 14kDa, 18kDa, 22kDa, 26kDa, 33kDa, 44kDa and70kDa. Double intensity bands: The 26kDa, 18kDa, 10kDa bands are at doubleintensity to make location and size approximation of proteins of interestquick and easy. Ready-to-use: No need to heat, dilute or add reducing agents before use.

121531

P07359.1

P07359

17.4kDa

ECM-receptor Interaction Pathway (83068); ECM-receptor Interaction Pathway (479); Formation Of Fibrin Clot (Clotting Cascade) Pathway (106057); GP1b-IX-V Activation Signalling Pathway (187205); Hematopoietic Cell Lineage Pathway (83078); Hematopoietic Cell Lineage Pathway (489); Hemostasis Pathway (106028); Intrinsic Pathway (106059); Platelet Adhesion To Exposed Collagen Pathway (106030); Platelet Aggregation (Plug Formation) Pathway (106053)

Glycoprotein Ib (GP Ib) is a platelet surface membrane glycoprotein composed of a heterodimer, an alpha chain and a beta chain, that is linked by disulfide bonds. The Gp Ib functions as a receptor for von Willebrand factor (VWF). The complete receptor complex includes noncovalent association of the alpha and beta subunits with platelet glycoprotein IX and platelet glycoprotein V. The binding of the GP Ib-IX-V complex to VWF facilitates initial platelet adhesion to vascular subendothelium after vascular injury, and also initiates signaling events within the platelet that lead to enhanced platelet activation, thrombosis, and hemostasis. This gene encodes the alpha subunit. Mutations in this gene result in Bernard-Soulier syndromes and platelet-type von Willebrand disease. The coding region of this gene is known to contain a polymophic variable number tandem repeat (VNTR) domain that is associated with susceptibility to nonarteritic anterior ischemic optic neuropathy. [provided by RefSeq, Oct 2013]

GPIbA: GP-Ib, a surface membrane protein of platelets, participates in the formation of platelet plugs by binding to the A1 domain of vWF, which is already bound to the subendothelium. Genetic variations in GP1BA may be a cause of susceptibility to non-arteritic anterior ischemic optic neuropathy (NAION). NAION is an ocular disease due to ischemic injury to the optic nerve. It usually affects the optic disk and leads to visual loss and optic disk swelling of a pallid nature. Visual loss is usually sudden, or over a few days at most and is usually permanent, with some recovery possibly occurring within the first weeks or months. Patients with small disks having smaller or non-existent cups have an anatomical predisposition for non-arteritic anterior ischemic optic neuropathy. As an ischemic episode evolves, the swelling compromises circulation, with a spiral of ischemia resulting in further neuronal damage. Defects in GP1BA are a cause of Bernard-Soulier syndrome (BSS); also known as giant platelet disease (GPD). BSS patients have unusually large platelets and have a clinical bleeding tendency. Defects in GP1BA are the cause of benign mediterranean macrothrombocytopenia (BMM); also known as autosomal dominant benign Bernard-Soulier syndrome. BMM is characterized by mild or no clinical symptoms, normal platelet function, and normal megakaryocyte count. Defects in GP1BA are the cause of pseudo-von Willebrand disease (VWDP). A bleeding disorder is caused by an increased affinity of GP-Ib for soluble vWF resulting in impaired hemostatic function due to the removal of vWF from the circulation. Protein type: Membrane protein, integral; Cell surface; Cell adhesion. Chromosomal Location of Human Ortholog: 17p13.2. Cellular Component: anchored to external side of plasma membrane; cell surface; membrane; integral to plasma membrane; plasma membrane. Molecular Function: protein binding; thrombin receptor activity. Biological Process: platelet activation; fibrinolysis; cell surface receptor linked signal transduction; regulation of blood coagulation; cell morphogenesis; cell adhesion; blood coagulation; blood coagulation, intrinsic pathway. Disease: Pseudo-von Willebrand Disease; Bernard-soulier Syndrome; Bernard-soulier Syndrome, Type A2, Autosomal Dominant; Nonarteritic Anterior Ischemic Optic Neuropathy, Susceptibility To

0.01 mg

200 USD

0.05 mg

430

0.1 mg

665